Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • AGEN1884: Phase I started

    Agenus Inc. (NASDAQ:AGEN), Lexington, Mass. Product: AGEN1884 Business: Cancer Molecular target: Cytotoxic T-lymphocyte associated protein 4 (CTLA4) (CD152) Description: Anti-cytotoxic T-lymphocyte associated protein 4…

    Published on 5/2/2016
  • AST-005: Phase I started

    Exicure Inc., Skokie, Ill. Product: AST-005 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) Description: Topical spherical nucleic acid-based therapeutic targeting tumor necrosis factor (TNF) …

    Published on 5/2/2016
  • BMN 250: Phase I/II started

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Product: BMN 250 Business: Endocrine/Metabolic Molecular target: N-acetylglucosaminidase alpha (NAGLU) Description: N-acetylglucosaminidase alpha (NAGLU) …

    Published on 5/2/2016
  • BPX-01: Completed Phase IIa enrollment

    BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Product: BPX-01 Business: Dermatology Molecular target: NA Description: Topical formulation of minocycline, a semisynthetic derivative of tetracycline Indication: Treat …

    Published on 5/2/2016
  • ESP-01: Phase Ib/IIa started

    Esperas Pharma Inc., Montreal, Quebec Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: ESP-01 (formerly LY2880070) Business: Cancer Molecular target: NA Description: Undisclosed oral compound that inhibits …

    Published on 5/2/2016
  • EVK-001: Completed Phase III enrollment

    Evoke Pharma Inc. (NASDAQ:EVOK), San Diego, Calif. Product: EVK-001 Business: Gastrointestinal Molecular target: Dopamine D2 receptor Description: Intranasal formulation of metoclopramide, a dopamine D2 receptor …

    Published on 5/2/2016
  • OMS721: Phase II started

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS721 Business: Renal Molecular target: Mannan-binding lectin-associated serine protease-2 (MASP-2) Description: Human mAb against mannan-binding lectin-associated …

    Published on 5/2/2016
  • Relamorelin: Completed Phase IIb enrollment

    Rhythm Holding Co. LLC, Boston, Mass. Ipsen Group (Euronext:IPN), Boulogne-Billancourt, France Product: Relamorelin (RM-131) (formerly BIM 28131) Business: Gastrointestinal Molecular target: Ghrelin Description: Ghrelin…

    Published on 5/2/2016
  • Anti-CX3CR1 Nanobody: Phase I started

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Anti-CX3CR1 Nanobody Business: Renal Molecular target: Chemokine CX3C motif receptor 1 (CX3CR1) Description: Nanobody …

    Published on 4/25/2016
  • Atezolizumab: Phase Ib amended

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Atezolizumab (Anti-PDL1) (MPDL3280A, RG7446) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-…

    Published on 4/25/2016
  • BI-505: Phase II started

    BioInvent International AB (SSE:BINV), Lund, Sweden Product: BI-505 Business: Cancer Molecular target: Intercellular adhesion molecule-1 (ICAM-1) (CD54) Description: Human mAb against intercellular adhesion molecule-1 (…

    Published on 4/25/2016
  • Contrave: Phase IV discontinued

    Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Product: Contrave ( Mysimba - EU) naltrexone SR/bupropion SR (NB32) Business: Endocrine/Metabolic Molecular target: Mu opioid receptor (MOR) (OPRM1) Description…

    Published on 4/25/2016
  • Fosfomycin: Pivotal trial started

    Zavante Therapeutics Inc., San Diego, Calif. Product: Fosfomycin (ZTI-01) Business: Infectious Molecular target: NA Description: IV fosfomycin, a broad-spectrum epoxide antibiotic Indication: Treat complicated urinary …

    Published on 4/25/2016
  • IdeS: Completed Phase II enrollment

    Hansa Medical AB (SSE:HMED), Lund, Sweden Product: IdeS Business: Transplant Molecular target: Immunoglobulin G (IgG) Description: Streptococcus pyogenes enzyme that cleaves IgG antibodies Indication: Prevent renal …

    Published on 4/25/2016
  • IMGN779: Phase I started

    ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass. Product: IMGN779 Business: Cancer Molecular target: CD33 Description: Antibody-drug conjugate (ADC) consisting of Z4681A, a humanized anti-CD33 antibody, conjugated to DGN462…

    Published on 4/25/2016
  • IV CR845: Phase III restarted

    Cara Therapeutics Inc. (NASDAQ:CARA), Shelton, Conn. Product: IV CR845 Business: Neurology Molecular target: Kappa opioid receptor (KOR) (OPRK1) Description: Long-acting peripheral kappa opioid receptor (KOR; OPRK1) …

    Published on 4/25/2016
  • MOR106: Phase I started

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium MorphoSys AG (Xetra:MOR), Martinsried, Germany Product: MOR106 Business: Inflammation Molecular target: NA Description: Human IgG1 mAb against an …

    Published on 4/25/2016
  • N-MCT N-methanocarbathymidine: Phase I started

    N&N Pharmaceuticals Inc., Rockville, Md. Product: N-MCT N-methanocarbathymidine Business: Infectious Molecular target: NA Description: Orally bioavailable thymidine analog with broad-spectrum antiviral activity …

    Published on 4/25/2016
  • Onapristone: Phase I/II discontinued

    Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc., Bridgewater, N.J. Product: Onapristone Business: Cancer Molecular target: Progestin receptor Description: Progestin receptor antagonist…

    Published on 4/25/2016
  • Subcutaneous GSK3196165: Phase II started

    MorphoSys AG (Xetra:MOR), Martinsried, Germany GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Subcutaneous GSK3196165 (formerly Subcutaneous MOR103) Business: Autoimmune Molecular target: Granulocyte …

    Published on 4/25/2016
  • Sym015: Phase I started

    Symphogen A/S, Copenhagen, Denmark Product: Sym015 Business: Cancer Molecular target: c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) Description: Mixture of 2 humanized IgG1 mAbs that bind to…

    Published on 4/25/2016
  • WT1 TCR-transduced T cells: Phase I/II ongoing

    Cell and Gene Therapy Catapult, London, U.K. Product: WT1 TCR-transduced T cells Business: Cancer Molecular target: Wilms tumor 1 (WT1) Description: Autologous T cell receptor (TCR)-transduced T cells targeting Wilms …

    Published on 4/25/2016
  • ADCT-402: Phase I started

    ADC Therapeutics S.a.r.l., Epilanges, Switzerland Product: ADCT-402 Business: Cancer Molecular target: CD19 Description: Antibody-drug conjugate (ADC) composed of a human mAb targeting CD19 and a pyrrolobenzodiazepine (…

    Published on 4/18/2016
  • Bekinda Ondansetron: Phase II started

    RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Tel Aviv, Israel Product: Bekinda Ondansetron (RHB-102) Business: Gastrointestinal Molecular target: Serotonin (5-HT3) receptor Description: Once-daily, extended-…

    Published on 4/18/2016
  • BioChaperone insulin: Phase I/II started

    Adocia S.A. (Euronext:ADOC; OTCQX:ADOCY), Lyon, France Product: BioChaperone insulin (HinsBet) Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Fast-acting formulation of recombinant …

    Published on 4/18/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993